News

Evidence-based recommendations on transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation. This involves implanting a replacement valve inside the faulty native valve ...
In 2023, a jury found that Medtronic infringed on a patent for a heart valve replacement method developed by Colibri Heart Valve.
The agency’s decision supports broader access to a minimally invasive treatment for patients with severe tricuspid ...
A patient forum identified the desire for better, earlier education as well as the toll on independence TR takes as it ...
Background Coarctation of the aorta (CoA) has good modern results, but large multicentre longitudinal data on outcomes, especially hospital resource utilisation through childhood and adolescence, are ...
The final Medicare coverage memo for transcatheter edge-to-edge repair for tricuspid valve regurgitation largely replicates the April 2025 draft, but cardiology centers will not have to bring an ...
Transcatheter aortic valve implantation (TAVI) is now an established treatment option for elderly patients with severe ...
RATES of permanent pacemaker implantation (PPI) exceed 20% in patients with aortic regurgitation (AR). A new retrospective ...
Transcatheter Aortic Valve Reintervention: Long-Term Outcomes in an Asian Cohort Presenter: Jie Jun Wong ...
Patients with heart failure and atrial fibrillation (AF) at the time of mitral transcatheter edge-to-edge repair (M-TEER) for ...
Edwards Lifesciences Corporation today announced the company's EVOQUE tricuspid valve replacement system has received Health Canada's approval for the treatment of tricuspid regurgitation (TR ...